Cosmos Health (NASDAQ:COSM) Announces Quarterly Earnings Results

Cosmos Health (NASDAQ:COSM) released its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.11), FiscalAI reports. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%.The company had revenue of $18.99 million for the quarter, compared to analysts’ expectations of $19.42 million.

Cosmos Health Trading Up 0.8%

Shares of NASDAQ:COSM traded up $0.00 during trading on Tuesday, reaching $0.21. The stock had a trading volume of 2,288,473 shares, compared to its average volume of 4,473,561. The business has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.30. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31. The stock has a market cap of $12.40 million, a P/E ratio of -0.32 and a beta of 4.80. Cosmos Health has a fifty-two week low of $0.16 and a fifty-two week high of $1.32.

Insider Activity at Cosmos Health

In other news, CFO Georgios Terzis bought 168,135 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average price of $0.25 per share, for a total transaction of $42,033.75. Following the completion of the transaction, the chief financial officer owned 2,235,398 shares in the company, valued at $558,849.50. The trade was a 8.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Grigorios Siokas bought 766,284 shares of the stock in a transaction on Wednesday, July 29th. The stock was purchased at an average cost of $0.18 per share, with a total value of $137,931.12. Following the completion of the purchase, the chief executive officer directly owned 14,248,092 shares in the company, valued at $2,564,656.56. This trade represents a 5.68% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 2,204,138 shares of company stock worth $457,137 in the last three months. Insiders own 26.15% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in COSM. Renaissance Technologies LLC boosted its holdings in shares of Cosmos Health by 260.5% during the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after purchasing an additional 241,775 shares during the last quarter. Citadel Advisors LLC increased its stake in Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after purchasing an additional 128,776 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares during the last quarter. Hedge funds and other institutional investors own 12.61% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.